Corcept Therapeutics Investors Urged to Secure Counsel Before Deadline

Rosen Law Firm reminds investors of April 21 lead plaintiff deadline in securities class action lawsuit against Corcept Therapeutics.

Apr. 18, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a calculator arranged on a clean white background, conceptually representing the gravity of a securities lawsuit against a pharmaceutical company.A legal case against a pharmaceutical company over misleading investor disclosures underscores the need for transparency and accountability in the industry.NYC Today

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025 of the important April 21, 2026 lead plaintiff deadline in a securities class action lawsuit against the company.

Why it matters

The lawsuit alleges that Corcept Therapeutics made misleading statements about the clinical trials supporting the use of its drug relacorilant, and that investors suffered damages when the true details about the FDA's concerns over the drug's approval entered the market.

The details

According to the lawsuit, Corcept Therapeutics represented that the key clinical trials for relacorilant provided 'powerful support' for the New Drug Application (NDA) submitted to the FDA, and that the company was confident the NDA would be approved. However, the lawsuit claims the FDA had repeatedly raised concerns about the adequacy of the clinical evidence, resulting in a known material risk that the relacorilant NDA would not be approved.

  • The class period is from October 31, 2024 to December 30, 2025.
  • The lead plaintiff deadline is April 21, 2026.

The players

Corcept Therapeutics Incorporated

A pharmaceutical company that develops and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

The Rosen Law Firm, P.A.

A global investor rights law firm that concentrates its practice in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“To join the Corcept class action, go to https://rosenlegal.com/submit-form/?case_id=51868 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq.

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”

— Laurence Rosen, Esq.

What’s next

The judge will decide on April 21, 2026 whether to allow the case to proceed as a class action lawsuit.

The takeaway

This case highlights the importance for investors to carefully evaluate the qualifications and track record of law firms representing them in securities class actions, as well as the need for pharmaceutical companies to be transparent about potential regulatory risks with their drug development pipelines.